Clinical Trials Logo

Filter by:
NCT ID: NCT06072053 Recruiting - Clinical trials for Chronic Subdural Hematoma

YL-1 Needle Puncture vs BHC With Postoperative Exhaustive Drainage for CSDH

NEBULA
Start date: December 22, 2023
Phase:
Study type: Observational

A prospective multicenter cohort study was designed to compare the differences in complications with YL-1 Needle Puncture versus Bulr-hole Craniotomy (BHC) with postoperative Exhaustive Drainage strategy for patients with Chronic Subdural Hematoma.

NCT ID: NCT06071403 Recruiting - Growth Retardation Clinical Trials

The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants

Start date: July 1, 2023
Phase:
Study type: Observational

This study aims to estimate short-term and long-term effects of time points to cease parenteral nutrition on very preterm infants, such as growth; to estimate the role of insulin-like growth factor 1 in the growth.

NCT ID: NCT06070857 Recruiting - Healthy Subjects Clinical Trials

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

Start date: October 5, 2023
Phase: Phase 1
Study type: Interventional

The study consists of 10 dose groups, 8 subjects in each group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and pharmacokinetics characteristics.

NCT ID: NCT06070740 Recruiting - Clinical trials for Gastrointestinal Neuroendocrine Carcinoma

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

First-Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma - a prospective Single-arm Phase II Study [NCT ID not yet assigned]

NCT ID: NCT06070636 Recruiting - Clinical trials for Hepatocellular Carcinoma

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with infiltrative hepatocellular carcinoma.

NCT ID: NCT06069349 Recruiting - Clinical trials for Patients After Cardiac Surgery

Timing of Mobilization on Delirium in Patients After Cardiac Surgery

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

Early mobilization is recommended because it is effective in improving symptoms for patients after cardiac surgery. However, the optimal timing of mobilization for postoperative patients is not unclear. How early is early? As early mobilization in the ICU is safe and may reduce healthcare costs, the goal was to assess the effect of early mobilization in the ICU on the incidence and duration of delirium.

NCT ID: NCT06069232 Recruiting - Clinical trials for Aortic Valve Disease

Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction

ARISTOTLE
Start date: March 1, 2021
Phase:
Study type: Observational

This study is a multicenter cohort study including patients diagnosed with aortic valve disease during hospitalization, including aortic insufficiency and aortic valve stenosis. The primary outcome of the study was all-cause death, and the secondary outcome was cardiovascular events. Through follow-up observation, the prognostic risk factors of patients with aortic disease were evaluated, and a prognostic model was constructed to guide clinical decision-making.

NCT ID: NCT06069180 Recruiting - Clinical trials for Severe Aplastic Anemia

The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA

Start date: November 15, 2023
Phase: Phase 4
Study type: Interventional

Hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA) -matched donor is an effective option for severe aplastic anemia (SAA), but there is no standardized and recommended conditioning regimen. The occurrence of mixed chimerism after transplantation is associated with secondary graft failure and poor failure-free survival. Previous studies have shown that Fludarabine (Flu)/ Cyclophosphamide (Cy)/ antithymocyte globulin (antithymocyte globulin), ATG) and Cy/ATG conditioning regimens had higher rates of mixed chimerism and poorer failure-free survival. A small cohort study has suggested that adding busulfan to Flu/Cy/ATG or Cy/ATG can reduce the incidence of mixed chimerism and improve failure-free survival. This study was a prospective, multicenter, randomized controlled trial to compare the efficacy and safety of different conditioning regimens in the treatment of severe aplastic anemia (SAA) after hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling or unrelated donor.

NCT ID: NCT06068621 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.

NCT ID: NCT06068465 Recruiting - Clinical trials for Parkinson's Disease Psychosis

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Start date: September 27, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).